Michelle Henley
About
In The Last Decade
Michelle Henley
12 papers receiving 591 citations
Peers
Comparison fields: 5 of 46
- Pulmonary and Respiratory Medicine 594
- Physiology 465
- Cardiology and Cardiovascular Medicine 25
- Endocrine and Autonomic Systems 22
- Complementary and alternative medicine 17
Countries citing papers authored by Michelle Henley
This map shows the geographic impact of Michelle Henley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michelle Henley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michelle Henley more than expected).
Fields of papers citing papers by Michelle Henley
This network shows the impact of papers produced by Michelle Henley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michelle Henley. The network helps show where Michelle Henley may publish in the future.
Co-authorship network of co-authors of Michelle Henley
This figure shows the co-authorship network connecting the top 25 collaborators of Michelle Henley. A scholar is included among the top collaborators of Michelle Henley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michelle Henley. Michelle Henley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 19 | |
| 2 | 14 | |
| 3 | 1 | |
| 4 | 63 | |
| 5 | 97 | |
| 6 | 66 | |
| 7 | 17 | |
| 8 | 314 | |
| 9 | 1 | |
| 10 | Benefits of dual bronchodilation with QVA149 once daily versus placebo, indacaterol, NVA237 and tiotropium in patients with COPD: The SHINE study | 8 |
| 11 | Effect of once-daily indacaterol in a predominantly Chinese COPD population: A 26-week Asia-Pacific study | 2 |
| 12 | 7 | |
| 13 | 3 | |
| 14 | The development of sodium cefoxitin as a dosage form. | 2 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.